Literature DB >> 11414636

Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa.

K Meijer1, F T Peters, J van der Meer.   

Abstract

A patient with von Willebrand's disease had recurrent gastrointestinal bleeding from angiodysplasia, with inadequate response to von Willebrand factor substitution, medical and endoscopic treatment, and resection of affected bowel. Frequent blood transfusions were required. She started home treatment with recombinant activated factor VII (rFVIIa) at the onset of bleeding, in addition to her standard therapy. From then on, bleeds could be controlled rapidly and no more blood transfusions were needed. We conclude that rFVIIa is effective in this case of angiodysplasia and might be a therapeutic option in similar patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11414636     DOI: 10.1097/00001721-200104000-00008

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  8 in total

1.  Small bowel angiodysplasia associated with von Willebrand's disease: report of a case.

Authors:  Rosalia Patti; Piero L Almasio; Salvatore Buscemi; Claudio Tripodo; Gaetano Di Vita
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

Review 2.  Pharmacological therapy of vascular malformations of the gastrointestinal tract.

Authors:  Andrew Szilagyi; Maged P Ghali
Journal:  Can J Gastroenterol       Date:  2006-03       Impact factor: 3.522

3.  Use of activated recombinant human factor VII (rhFVIIa) for colonic polypectomies in patients with cirrhosis and coagulopathy.

Authors:  Abhinandana Anantharaju; Kapil Mehta; Ayse L Mindikoglu; David H Van Thiel
Journal:  Dig Dis Sci       Date:  2003-07       Impact factor: 3.199

Review 4.  Aortic stenosis and anemia with an update on approaches to managing angiodysplasia in 2018.

Authors:  Kevin Mohee; Omar Aldalati; Rafal Dworakowski; Hasan Haboubi
Journal:  Cardiol J       Date:  2018-07-16       Impact factor: 2.737

Review 5.  Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.

Authors:  R Michael Grounds; Charles Bolan
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

6.  Bleeding recurrence in patients with gastrointestinal vascular malformation after thalidomide.

Authors:  Haiying Chen; Sengwang Fu; Nan Feng; Huimin Chen; Yunjie Gao; Yunjia Zhao; Hanbing Xue; Yao Zhang; Xiaobo Li; Jun Dai; Jingyuan Fang; Zhizheng Ge
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 7.  Management of Stroke risk in atrial fibrillation patients with bleeding on Oral Anticoagulation Therapy-Role of Left Atrial Appendage Closure, Octreotide and more.

Authors:  Tawseef Dar; Bharat Yarlagadda; James Vacek; Buddhadeb Dawn; Dhanunjaya Lakkireddy
Journal:  J Atr Fibrillation       Date:  2017-12-31

Review 8.  Von Willebrand factor in patients on mechanical circulatory support - a double-edged sword between bleeding and thrombosis.

Authors:  Bartosz Hudzik; Jacek Kaczmarski; Jerzy Pacholewicz; Michal Zakliczynski; Mariusz Gasior; Marian Zembala
Journal:  Kardiochir Torakochirurgia Pol       Date:  2015-09-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.